Clinical Trial

Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC

Name: Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC — clinical trial record (NCT06816966)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CISART

Enrolling by Invitation Phase 2

View on ClinicalTrials.gov →

Summary

This study is a prospective, single-arm, phase Ⅱ trial evaluating the safety and efficacy of Chemotherapy-immunotherapy-based split-course adaptive hypofractionated radiotherapy for extensive-stage SCLC

Trial Details

NCT Number	NCT06816966
Lead Sponsor	Fujian Medical University Union Hospital
Conditions	Small-cell Lung Cancer
Enrollment	35 participants
Start Date	2023-12-26
Primary Completion	2026-10-31 (estimated)
Study Completion	2028-10-31 (estimated)
Updated on ClinicalTrials.gov	2025-02-10